Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes

Proteomics for precision medicine: Next-generation testing to
indicate future cardiovascular risk and improve outcomes

Proteomic testing can reveal multiple answers to clinical questions that allow providers to better predict, monitor, and prevent the escalation of cardiovascular disease (CVD). This allows providers to move the needle away from the practice of late-stage treatment and toward treating at-risk patients sooner and before a major cardiovascular (CV) event.

Topics covered include:

  • The capabilities of proteomics
  • How comprehensive protein detection technology can accurately predict major cardiovascular events
  • How proteomic testing can ultimately improve outcomes

Image of Nelson Trujillo, MD

Nelson Trujillo, MD

Cardiologist
Boulder Heart at Anderson Medical Center

Image of Rosalynn Gill, PhD

Rosalyn Gill, PhD

Vice President, Medical Affairs
SomaLogic, Inc.

Image of Todd Johnson EVP SomaLogic

Todd Johnson

Executive Vice President, Diagnostics
Business Unit
SomaLogic, Inc.

Proteomics for precision medicine: Next-generation testing to indicate future cardiovascular risk and improve outcomes

A presentation by Nelson Trujillo, MD, Rosalyn Gill, PhD, and Todd Johnson

Share with colleagues

More webinars

WebinarAccelerating precision medicine of cancer with SomaScan® proteomics

Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology -- the SomaScan Platform, which measures 7,000 proteins -- to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.

Learn more

WebinarImproving clinical development productivity with high-plex proteomics

While the vast majority of approved pharmaceuticals target proteins, knowledge of the full complement of proteins that are acted on by drugs, or are potentially druggable, remains incomplete. Assessment of the human proteome is thus increasingly recognized as a priority for successful and cost-effective drug development and clinical research.

Learn more

WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program

How SomaLogic Technologies can give your research programs an edge

Learn more